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Interventional Strategies for
ST-Segment Elevation
Myocardial Infarction and
Multivessel Coronary
Artery Disease*
John A. Bittl, MD
Ocala, Florida
Many patients with ST-segment elevation myocardial in-
farction (STEMI) have multivessel coronary artery disease
(CAD) (1,2), yet interventional cardiologists can almost
always identify a single lesion responsible for the infarction.
After successful percutaneous coronary intervention of the
infarct-related lesion (culprit PCI), there are 2 competing
strategies available for STEMI patients with multivessel
CAD. Additional lesions in noninfarct vessels can be
treated immediately at the same sitting (multivessel PCI) or
they can undergo delayed evaluation and treatment during
another session (staged PCI).
See pages 692 and 704
Practice guidelines concerning multivessel PCI during
STEMI written by the major cardiac societies are similar in
intent but different in tone and classification. The writing
group for the American College of Cardiology Foundation
and American Heart Association makes a restrictive “thou
shalt not” recommendation by stating, “PCI should not be
performed in a noninfarct artery at the time of primary PCI
in patients without hemodynamic compromise. (Class III
Harm, Level of Evidence: B)” (3). The writing group for the
European Society of Cardiology and the European Associ-
ation for Cardio-Thoracic Surgery makes a more permissive
“thou shalt” recommendation by stating, “With the excep-
tion of cardiogenic shock, PCI for STEMI should be
limited to the culprit stenosis (Class IIa, Level of Evidence:
B)” (4). Although the language differences seem trivial, the
classification differences (Class III Harm vs. Class IIa)
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significant implications for practice appropriateness.
Most evidence against performing multivessel PCI dur-
ing STEMI has been indirect or retrospective. Mechanistic
studies suggest a cautious approach, because lesions in
noninfarct arteries appear to be more severe (5) and flow in
noninfarct vessels to be more reduced (6) during an acute
MI than in the absence of an MI. Hanratty et al. (5)
reported that in 21% of patients, lesions initially assessed as
50% during infarct angiography became 50% during
noninfarct angiography (5).
Retrospective analyses also support a cautious approach to
multivessel PCI during STEMI. In a cohort analysis pub-
lished in this issue of the Journal, Kornowski et al. (7) report
that multivessel PCI performed in the HORIZONS-AMI
(Harmonizing Outcomes with Revascularization and Stents
in Acute Myocardial Infarction) trial was associated with a
higher 1-year mortality (9.2% vs. 2.3.%) and stent throm-
bosis rate (5.7% vs. 2.3%) than staged PCI. And in a
meta-analysis published in this issue of the Journal, Vlaar et
al. (8) report that multivessel PCI was associated with a 60%
higher risk of long-term mortality than culprit PCI (odds
ratio [OR]: 1.6, 95% confidence interval [CI]: 1.3 to 2.0).
Multivessel PCI was also associated with a higher long-term
mortality than staged PCI (OR: 5.3, 95% CI: 2.3 to 122).
Multivessel PCI in practice. Whereas retrospective stud-
ies report unfavorable outcomes and guidelines discourage
multivessel PCI during nonshock STEMI, the practice
remains relatively common. In the HORIZONS-AMI
study, 18.5% of patients underwent multivessel PCI but
only 1.5% had cardiogenic shock (7). In the APEX AMI
(Assessment of Pexelizumab in Acute Myocardial Infarc-
tion) trial, 9.9% of patients underwent multivessel PCI (1)
ut only 1.0% was in Killip class IV (9). In the New York
tate Registry, 12.5% underwent multivessel PCI, but only
.4% met the definitions of hemodynamic compromise (10).
Reasons for the use of multivessel PCI in 10% to 20% of
TEMI cases cannot be explained by financial incentives,
hich would favor the strategy of staged PCI, but may be
xplained by the presence multiple complex lesions that
ppear to be pathogenic (2). Patients who die of MI often
ave 1 culprit lesion. In an autopsy series of 100 patients,
avies and Thomas (11) observed 115 separate thrombi in
4 patients and concluded that the majority of patients who
ie within 6 h of MI have “one or more rapidly developing
rterial lesions.” In some cases, identifying a single culprit
esion in the presence of multivessel CADmay be hampered
y the variable ability of the electrocardiogram to localize
nfarctions (12). While ST-segment elevation in 2 or more
f leads I, aVL, or V1 to V4 may be predictive of disease in
the left anterior descending artery (LAD), ST-segment
elevation in 2 or more of leads II, III, or aVF may not
distinguish between disease in the right coronary, the distal
LAD, or the left circumflex coronary artery (12). Lateral
MIs with ST-segment elevation in leads I and aVL may be
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Limited evidence. Patients undergoing culprit PCI, mul-
tivessel PCI, or staged PCI are inherently different from
each other. The STEMI patients with multivessel CAD
have higher mortality rates than patients with single-vessel
CAD (13). Patients undergoing multivessel PCI have lower
ejection fractions than patients undergoing staged PCI
(50% vs. 55%) (7).
Cohort studies, based on the analysis of records, cannot
identify the reasons for the selection of 1 PCI strategy over
another. In the HORIZONS-AMI trial analysis (7), “the
specific reasons why operators chose a single procedure vs. a
staged approach were not prospectively collected.” Although
many demographic features may have been similar between
the treatment groups (8), other variables such as multiple
complex lesions, left ventricular dysfunction, or persistent
hemodynamic instability are more common in patients
undergoing multivessel PCI. By failing to consider such
covariates, cohort studies are susceptible to confounding.
Meta-analyses accrete the confounding effects and overstate
the strength and precision of individual-trial results (14).
Statistical adjustments cannot eliminate confounding when
treatment decisions are based on unmeasured variables, and
propensity analyses cannot produce accurate models if few
patients have overlapping risks. When confounding occurs,
as in the classic case of hormonal replacement therapy for
cardiac prevention in postmenopausal women, cohort stud-
ies may yield different results than controlled trials.
In the current meta-analysis (8), the results of the large
cohort studies seem to disagree with the results of smaller
prospective studies. The pooled results of 9 cohort studies of
5,128 patients (8) suggested higher long-term mortality
after multivessel PCI than after culprit PCI (OR: 1.8, 95%
CI: 1.4 to 2.2), whereas pooled results of 3 prospective
studies of 288 patients suggested no difference (OR: 0.7,
95% CI: 0.3 to 1.6). No prospective trial was large enough
to show a significant mortality difference, but a randomized
trial (15) reported nominally lower mortality rates after
multivessel PCI than after culprit PCI (9.2% vs. 15.5%).
The results of the current meta-analysis (8) also appear to
contradict the conclusions of other contemporary meta-
analyses (16,17), which suggest no difference in long-term
mortality rates after multivessel PCI or culprit PCI (OR:
1.1, 95% CI: 0.8 to 1.6). Because of methodological
differences, “it is not uncommon to find that 2 or more
meta-analyses done at about the same time by investigators
with the same access to the literature reach incompatible or
even contradictory conclusions” (14). Interpreting conflict-
ing trial results remains challenging, but framing the prob-
lem within the clinical context may provide perspective.
Practical considerations. Practice guidelines define a stan-
dard, but they are not commandments. No single approach
is applicable to the myriad presentations of STEMI. How-
ever, a reasonable first step (despite the pressure to shorten
door-to-balloon times) involves both right and left coronaryangiography with diagnostic catheters to assess the entire
coronary anatomy before a lesion is targeted for PCI. After
culprit PCI, almost all patients show improvement. Patients
with severe multivessel CADmay require follow-up angiog-
raphy. Fractional flow reserve can be considered during the
acute phase (18), but the results should be used whenever
possible to support a decision for staged PCI.
Practice guidelines do not support the practice of multi-
vessel PCI during nonshock STEMI (3,4). However, no set
of recommendations governs the treatment of every patient
in every clinical situation. Multivessel PCI may be necessary
in some STEMI patients who have multiple complex
lesions and do not improve after culprit PCI.
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